KH-CB19

• UNSPSC Description:

  KH-CB19 is a potent CLK (cdc2-like kinase) inhibitor (CLK1 IC50=19.7 nM; CLK3 IC50=530 nM). KH-CB19 shows antiviral activity and inhibits influenza virus replication (IC50=13.6?μM)[1][2].

• Target Antigen:

  CDK

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Field of Research:

  Infection; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/KH-CB19.html

• Purity:

  99.31

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  CCOC(C1=C(C2=C(C(Cl)=C(C=C2)Cl)N1C)/C(C#N)=C\N)=O

• Molecular Weight:

  338.19

• References & Citations:

  [1]Fedorov O, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76.|[2]Artarini A, et al. Regulation of influenza A virus mRNA splicing by CLK1. Antiviral Res. 2019 Aug;168:187-196.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1354037-26-5